Razazian 2016.

Methods	Study design: parallel design Number of arms: 2 Treatment arm: fluoxetine (SSRI) Control arm: matched placebo
Participants	Geographical location: Iran Setting: inpatient Stroke criteria: acute Ischemic stroke, in MCA region Method of stroke diagnosis: confirmed by radiological imaging (CT) Time since stroke: not reported Inclusion criteria: 1) stroke in MCA region that leads to monoparesis, hemiparesis or hemiplegia, 2) stable condition Exclusion criteria: 1) death, 2) pregnancy, 3) poor compliance with drugs and physiotherapy, 4) potential drug complications, 5) metabolic disease, 6) stroke in anterior cerebral artery or posterior cerebral artery Depression criteria: not reported. Total number randomised in this trial: 172 Number randomised in treatment group: 86 Number randomised to control group: 86 Total number included in final analysis: 150 Number included in treatment group for final analysis: 75 Number included in control group for final analysis: 75
Interventions	Treatment: fluoxetine (SSRI) 20 mg once per day orally Control: matched placebo Treatment duration: 90 days Follow‐up: not reported
Outcomes	Primary outcome Depression measured using the HDRS Secondary outcomes Activities of daily living measured using the BI Neurological examinations
Notes

BDI: Beck Depression Inventory

BI: Barthel Index

CNS: central nervous system

CT: computed tomography

HDRS: Hamilton Depression Rating Scale

MCA: middle cerebral artery

MMSE: Mini Mental State Examination

MRI: magnetic resonance imaging

mRS: Modified Rankin Scale

NIHSS: National Institute of Health Stroke Scale

SD: standard deviation

SSRI: Selective Serotonin Reuptake Inhibitors

USA: United States of America